Galcanezumab shows similar pregnancy outcomes to placebo, highlighting the need for more real-world safety data in patients ...

Once-daily rimegepant 75 mg is effective and well-tolerated for short-term prevention of fasting-related headache in adults ...

Atogepant 60 mg vs rimegepant and galcanezumab for episodic migraine prevention has superior efficacy, with comparable safety ...

Atogepant 60 mg once daily leads to meaningful weight loss in patients with overweight or obesity receiving preventive ...

STS101 nasal powder, DHE, delivers fast, lasting relief from cardinal migraine symptoms, including photophobia, phonophobia, ...

A 75% plus increase in good days/month with eptinezumab is associated with improved migraine symptoms, brain fog, and overall ...

MR is associated with better treatment response than gepants in patients with migraine who previously had an inadequate ...

Patients with migraine with aura show reduced migraine symptoms, less rescue medication use, and more sustained pain relief ...

Most pediatric patients with migraine have normal imaging, supporting that routine scans rarely aid diagnosis or alter ...

CoQ10 supplementation is associated with headache resolution among pediatric patients with new daily persistent headache.

Among children and adolescents with episodic migraine, fremanezumab significantly reduced monthly migraine days.

Psilocybin therapy improved cognitive performance, reduced mood dysfunction, motor, and nonmotor symptoms in patients with Parkinson disease.